Actively Recruiting
Evaluating ACR-368 Alone or with Low-Dose Gemcitabine for Treatment of Endometrial Cancer A Phase 2 Study Assessing Safety and Efficacy Based on Tumor Sensitivity
Led by Acrivon Therapeutics · Updated on 2026-08-21
350
Participants Needed
90
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of ACR-368, either alone or combined with ultra-low dose gemcitabine ULDG sensitization, in adults with high-grade endometrial cancer. This Phase 2 open-label study divides participants into four groups based on tumor characteristics and prior test results to better understand treatment responses. Participants are assigned to one of four groups two based on tumor sensitivity predicted by the OncoSignature test, and two without this selection. Those in Arms 1 and 4 receive ACR-368 alone, while Arms 2 and 3 receive ACR-368 combined with ULDG sensitization. Treatment continues until disease progression, unacceptable side effects, or withdrawal. During the study, participants undergo tumor response assessments every 8 weeks for up to 2 years or until death. Safety is monitored through adverse event tracking and limited pharmacokinetic testing. Researchers also observe overall survival, duration of response, and progression-free survival throughout the follow-up period ending at 2 years.
CONDITIONS
Brief Title
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Research Team
M
Mansoor Raza Mirza, MD
J
Jeanie Tang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here